ICOS Icos

ICOS Corporation (Nasdaq:ICOS) announced today that it will participate in the UBS Global Life Sciences Conference on Wednesday, September 28, 2005. The presentation, which may include financial guidance and plans for the remainder of 2005, will be webcast. -0- *T UBS Global Life Sciences Conference Presentation Date: September 28, 2005 Time: 3:30 p.m. EDT Speaker: Paul N. Clark, Chairman, President and Chief Executive Officer *T A webcast of this ICOS presentation will be available in real-time and a replay will be available through Oct. 5, 2005. The webcast can be accessed through the ICOS Web site, www.icos.com, Investor - Events section. Additional information on ICOS, including past press releases, is also available at www.icos.com. About ICOS Corporation: ICOS Corporation, a biotechnology company headquartered in Bothell, Washington, is dedicated to bringing innovative therapeutics to patients. Through Lilly ICOS LLC, ICOS is marketing its first product, Cialis(R) (tadalafil), for the treatment of erectile dysfunction. ICOS is working to develop treatments for serious unmet medical conditions such as pulmonary arterial hypertension, benign prostatic hyperplasia, cancer and inflammatory diseases. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause ICOS' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with product commercialization, manufacturing activities, clinical development, regulatory approvals, intellectual property claims and litigation and other risks detailed in ICOS' latest Quarterly Report on Form 10-Q and its other SEC filings.